These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18054053)

  • 1. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
    Nordquist RE; Risterucci C; Moreau JL; von Kienlin M; Künnecke B; Maco M; Freichel C; Riemer C; Spooren W
    Neuropharmacology; 2008 Feb; 54(2):405-16. PubMed ID: 18054053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
    Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
    Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z; Ichikawa J; Dai J; Meltzer HY
    Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
    Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A
    Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
    Bruins Slot LA; Kleven MS; Newman-Tancredi A
    Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
    J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
    Ballmaier M; Zoli M; Mazzoncini R; Gennarelli M; Spano F
    Psychopharmacology (Berl); 2001 Dec; 159(1):105-10. PubMed ID: 11797077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia.
    Neves G; Antonio CB; Betti AH; Pranke MA; Fraga CA; Barreiro EJ; Noël F; Rates SM
    Behav Brain Res; 2013 Jan; 237():86-95. PubMed ID: 23000351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats.
    Nakai S; Hirose T; Mori T; Stark A; Araki H; Kikuchi T
    Int J Neurosci; 2008 Jan; 118(1):39-57. PubMed ID: 18041605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist.
    Feifel D; Reza TL; Wustrow DJ; Davis MD
    J Pharmacol Exp Ther; 1999 Feb; 288(2):710-3. PubMed ID: 9918579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.